IPF
Clinical trials for IPF explained in plain language.
Never miss a new study
Get alerted when new IPF trials appear
Sign up with your email to follow new studies for IPF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for lung scarring disease in early trial
Disease control Recruiting nowThis study tests an experimental drug called SB17170 in 30 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. The goal is to see if the drug can improve lung function compared to a placebo over 12 weeks. Participants will …
Matched conditions: IPF
Phase: PHASE2 • Sponsor: SPARK Biopharma • Aim: Disease control
Last updated May 17, 2026 02:56 UTC
-
New inhaled therapy for scarred lungs enters first human tests
Disease control Recruiting nowThis early-stage study tests an inhaled drug called AGMB-447 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal is to check safety and how the body handles the drug. About 145 participants will receive either the drug…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Agomab Spain S.L. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Virtual workouts tested for lung disease relief
Symptom relief Recruiting nowThis study looks at whether two types of home exercise programs (live online sessions or pre-recorded videos) can improve breathing and daily function in people with idiopathic pulmonary fibrosis (IPF). About 44 adults with stable IPF will be randomly assigned to one of the two g…
Matched conditions: IPF
Phase: NA • Sponsor: Istanbul Medipol University Hospital • Aim: Symptom relief
Last updated May 14, 2026 12:04 UTC
-
Can a simple blood test predict lung scarring? new study seeks answers
Knowledge-focused Recruiting nowThis study is looking for early warning signs that lung scarring (fibrosis) is getting worse in people with various types of interstitial lung disease. Researchers will follow 450 adults over time, using blood tests, breathing tests, CT scans, and breath analysis to find markers …
Matched conditions: IPF
Sponsor: Amsterdam UMC, location VUmc • Aim: Knowledge-focused
Last updated May 17, 2026 03:08 UTC
-
New drug HW241045 takes first step: safety check in healthy volunteers
Knowledge-focused Recruiting nowThis early-phase study tests the safety and tolerability of a single dose of HW241045 in 56 healthy adults aged 18-55. Participants are randomly assigned to receive either the drug or a placebo, and researchers monitor for side effects. The goal is to gather initial safety data b…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Knowledge-focused
Last updated May 06, 2026 16:03 UTC